VistaGen Therapeutics stands
at the forefront of the biotech industry today with their human pluripotent
stem cell (hPSC) differentiation capabilities, which allow the company to
produce a wide variety of functional adult human cells that can be used to
benchmark complex disease behaviors and drug interactions. The company’s
current emphasis is on the highly-lucrative drug rescue space (using small
molecule drug candidates), where a vast stockpile of once-promising (yet
discontinued) drugs exists, which are soon to be joined by yet more
discontinued New Molecular Entities (NMEs) rejected by the FDA. Helping
companies offset massive R&D outlays that fail to come to fruition due to
toxicity and other complications, via their proprietary hPSC-enabled Human
Clinical Trials in a Test Tube™ platform, VSTA is able to assist major players
like Bayer (OTCM: BAYRY), GlaxoSmithKline (NYSE: GSK), Johnson & Johnson
(NYSE: JNJ) and Roche (OTCM: RHHBY), as well as smaller pharma developers, to
recoup the increasingly high levels of R&D investment required to develop
new drugs, offering comprehensive in vitro 3D “micro-organ” culture assay
systems like their CardioSafe 3D™.
Predictive toxicology and
drug metabolism assessment via 3D bioassays made of real human cells provides
an unprecedented power to evaluate a given drug candidate well before expensive
human trials ever begin. Technology like VSTA’s CardioSafe 3D represents over a
decade and a half of applied science know how in hSPC differentiation between
the company and its collaborators, and is a revolutionary leap beyond generally
underperforming 2D cultures. The capacity to grow normal, non-transformed,
human heart cells (cardiomyocytes) in a framework that produces intact 3D cell
networks and tissue structures, more accurately models the structures and
biology within the human body itself, resulting in heretofore unknown degrees
of testing accuracy. Moreover, CardioSafe 3D is faster, in addition to being
more accurate, making clinically relevant predictions for both toxic and
non-toxic effects in cardiac tissue at rates virtually unattainable elsewhere.
This same technology stands
behind VSTA’s other leading bioassay platform, LiverSafe 3D™, which uses
mature, hSPC-derived liver cells (hepatocytes), solidly addressing one of the
top two causes for drug failure, liver toxicity and adverse drug metabolism
results. The underlying technology gives VSTA a developmental footprint that
spans pharmaceutical applications ranging from stem cell-derived blood, to
bone, cartilage, and even pancreatic beta-islet cells as well, ultimately
dovetailing with the regenerative medicine space, where stem cell technology
represents a huge future market. The regenerative medicine space is
particularly attractive for VSTA as they will be able to do novel models for
human disease, potentially leading to breakthrough new small molecule drug
developments, as well as biologics that can trigger endogenous tissue repair
and healing, effectively combating what are otherwise essentially untreatable
degenerative diseases.
In the U.S. during 2013
alone the pharma sector dumped over $51B in R&D into new drug development,
yet the FDA’s Center for Drug Evaluation and Research (CDER) approved only 27
NMEs, 13 of which went to the top five pharma players. In addition, competition
from generics on expired drug patents, combined with the extant R&D costs
and progressively diminishing product pipelines, puts a sharp focus on VSTA’s
new and safer developing Drug Rescue Variants™. After spending millions of
dollars and sometimes decades developing a new drug, it is a huge blow to a
given company’s bottom line to have to discontinue development and marketing
due to bad drug interactions or toxicity.
The fundamental trends in
this space all add up to a very bright future for VSTA and the company’s recent
(Apr 23) announcement that the USPTO issued a Notice of Allowance for their
“Cell populations enriched for endoderm cells” (application 12/836,275),
further reinforces VSTA’s already strong IP position, handsomely complementing
existing patents licensed exclusively by VSTA from the Icahn School of Medicine
at Mount Sinai in NY (#7,763,466, #8,512,957 and #8,143,009). This latest
announcement regarding expansion of VSTA’s stem cell tech IP protection
strengthens their LiverSafe 3D platform considerably and highlights the
company’s world-class proficiency in hSPC differentiation, placing VSTA in the
pole position when it comes to executing future collaborative efforts in the
liver biology and drug metabolism assay arena. It also sets VSTA up nicely for
regenerative cell therapy and drug applications using pancreatic beta-islet
cells to address diabetes, a condition from which over 8.3% of the U.S.
population suffered last year alone (25.8M diabetics) and which threatens as
many as 79M Americans, who are pre-diabetic according to the same ADA® data.
The company’s AV-101
(L-4-chlorokynurenine) small molecule prodrug candidate for neurological
disease and disorders has successfully exited Phase 1 development (aided by
some $8.8M in grant funding from the NIH) and represents a godsend for chronic
neuropathic pain patients, who must contend not only with broad-spectrum
difficulties due to a compromised central nervous system, but attendant
epileptic phenomena and depression as well. AV-101 is a huge out-licensing
candidate for development and marketing that investors should keep an eye on,
but the potential for VSTA’s hSPC-based bioassays in drug development are even
more profound and deserve even greater consideration.
More info on VistaGen
available at www.vistagen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
